L'Oréal warns that the boom in Ozempic and other GLP-1 drugs is changing cosmetics consumption
The boom in weight-loss drugs such as Ozempic, Wegovy and Mounjaro is changing the consumption of beauty products, especially skincare, according to L'Oréal. Its CEO, Nicolas Hieronimus, called GLP-1 drugs "a very important phenomenon" for the company during an investor call. The French firm already offers products aimed at skin sagging linked to rapid weight loss and raised its stake in Galderma to 20%. Its sales grew 7.7% in the quarter ended in September.
In 35 seconds
- L'Oréal says widespread use of GLP-1 drugs affects beauty product consumption, especially skincare
- Rapid weight loss can cause skin sagging, driving demand for new products and treatments
- The company raised its stake in Galderma, which specializes in dermatology and aesthetic medicine, to 20%
IASummary generated by artificial intelligence from a story by BioBioChile. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.